Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics (Nasdaq: BNGO) announced a significant presence at the upcoming European Society of Human Genetics (ESHG) conference, with 11 customer presentations showcasing optical genome mapping (OGM) data. These presentations will span three key clinical areas: hematological malignancies, inherited genetic disorders, and solid tumor analysis, highlighting the advanced capabilities of Bionano's Saphyr® system in detecting structural variants. The virtual event runs from August 28 to August 31, 2021, and aims to enhance understanding of OGM's clinical utility compared to traditional cytogenetics methods.
Bionano Genomics reported strong financial results for Q2 2021, achieving a 226% year-over-year revenue increase to $3.9 million. This growth was driven by the expansion of the Saphyr installed base, which now totals 121 systems. Cash reserves stood at $333 million as of June 30, 2021. Key highlights include the shipment of 13 Saphyr systems, significant sales in nanochannel array flow cells, and a growing presence in global cytogenetics markets. The company is focused on enhancing market adoption and reimbursement strategies as it progresses toward its 2021 milestones.
Bionano Genomics (BNGO) announced a conference call on August 4, 2021, at 4:30 p.m. ET, to discuss its second-quarter financial results ending June 30, 2021, and recent corporate achievements. Participants can join via a toll-free line or through a live webcast. The Saphyr system, utilized for genomic analysis, continues to enhance research capabilities, aiding in diagnostics for neurodevelopmental disorders through its Lineagen business, which has conducted over 65,000 genetic tests.
Bionano Genomics (BNGO) announced a record number of 10 optical genome mapping (OGM) presentations at the Cancer Genomics Consortium (CGC) meeting from August 1-4, 2021. This year's CGC is expected to exceed 500 attendees, showcasing the increasing adoption of OGM for clinical research in solid tumors, hematological malignancies, and genetic testing. Notable presentations include discussions on the benefits of OGM over traditional methods, highlighting its sensitivity and workflow efficiency. CEO Erik Holmlin emphasized the significance of Bionano's growing presence in cancer research.
Bionano Genomics (BNGO) reports results from a University Hospitals Leuven study demonstrating the effectiveness of their Saphyr system in analyzing acute lymphoblastic leukemia (ALL). The optical genome mapping (OGM) technique showed a 100% concordance with traditional methods and reduced turnaround time from 4 weeks to 1 week. Key findings include a 50% reduction in cost per sample, a higher assay success rate, and additional pathogenic findings in 5% more cases. The study supports future OGM-based assays for leukemia and other conditions.
Bionano Genomics (Nasdaq: BNGO) presented data at the 2021 European Cytogenomics Conference, showcasing the advantages of optical genome mapping (OGM) over traditional cytogenetics in leukemia research. Key studies revealed 100% concordance in pediatric leukemia diagnoses, uncovering new clinically relevant information in 60% of cases. OGM also demonstrated improved prognostic capabilities in chronic lymphocytic leukemia, with 45% of cases benefiting from additional insights. Overall, the findings underscore OGM's potential to enhance diagnostic accuracy and treatment strategies in hematological malignancies.
Bionano Genomics (BNGO) showcased its optical genome mapping (OGM) technology at the 2021 European Cytogenomics Conference (ECA), indicating its increasing adoption for genomic analysis in leukemia and genetic diseases. The event featured nine presentations highlighting OGM's advantages, such as 100% concordance with traditional techniques and significant cost and time reductions. Key findings included enhanced prognostic accuracy and identification of clinically relevant variants. CEO Erik Holmlin emphasized the potential for OGM's continued expansion in clinical research applications.
Bionano Genomics (Nasdaq: BNGO) announced two significant peer-reviewed studies published in the American Journal of Human Genetics. Conducted by leading European institutions, these studies validate the effectiveness of optical genome mapping (OGM) as a superior method for analyzing structural variants (SVs) in genetic diseases and hematological malignancies. OGM demonstrated 100% concordance with traditional methods like FISH and karyotyping, offering enhanced resolution for detecting variants. The research emphasizes OGM's potential to revolutionize cytogenetic analysis and its ready application in clinical settings.
Bionano Genomics (BNGO) has made strides in the Chinese market with the adoption of its Saphyr® System for optical genome mapping (OGM) by WeHealth Shanghai. Announced at the Structural Variation Symposium, WeHealth highlighted the launch of a comprehensive genome-analysis offering. Key presentations included successful applications of OGM for prenatal testing in muscular dystrophy and improved diagnostic workflows for hemophilia A.
CEO Erik Holmlin emphasized the company’s ongoing investment in commercial operations in China, aiming for expanded adoption of Saphyr in the reproductive health sector.
Bionano Genomics (Nasdaq: BNGO) announced participation in the 6th Annual International Conference of the Board of Genetic Counseling India from July 2-4, 2021. Chief Medical Officer Dr. Alka Chaubey will discuss optical genome mapping (OGM) in genetic counseling on July 3 at 9:25 am IST. Dr. Yassmine Akkari will present on OGM's role in Acute Myelogenous Leukemia at 4:10 pm IST the same day. The conference promotes genetic education and has over 2,000 global delegates. Bionano is a Diamond Sponsor of the event.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
